Satellos Bioscience Inc. (MSCLF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director | 584.16k | -- | 1955 |
| Ms. Elizabeth Williams C.A., CPA | CFO & Corporate Secretary | 247.02k | -- | 1978 |
| Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer | 624.51k | -- | 1969 |
| Mr. William Wasyl Jarosz | Executive Director | 134.97k | -- | 1956 |
| Mr. Warren Whitehead C.M.A., CPA | Head of Corporate Strategy | 226.39k | -- | 1952 |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Discovery Officer | 86.65k | -- | 1962 |
| Mr. J. Robert Hall CFA | Senior Vice President of Finance & Administration | -- | -- | -- |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor | 32.12k | -- | 1960 |
| Ms. Desiree Chan | Chief of Staff | -- | -- | -- |
| Ms. Courtney Wells | Senior Vice President of Clinical Development Operations | -- | -- | -- |
Satellos Bioscience Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI) for the rights and license to a body of technology and patents comprised of five patent families; and an option agreement with the University of British Columbia to negotiate a license for the rights to the Oral Amp B delivery system. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available